Heart Attack

71% of Self-identified Snorers Have Never Consulted a Healthcare Professional

National survey identifies major obstacles to treating snoring and sleep issuesPLEASANTON, Calif., June 28, 2023 (GLOBE NEWSWIRE) -- ProSomnus, Inc.…

1 year ago

The Montreal Heart Institute Welcomes FDA Approval of Colchicine for the Treatment of Cardiovascular Diseases

MONTREAL, June 23, 2023 (GLOBE NEWSWIRE) -- The Montreal Heart Institute (MHI) welcomes the approval by the United States Food…

1 year ago

Marius Pharmaceuticals Supports AXYS 2023 Virtual Family Conference, Spotlighting KYZATREX™ for XY Chromosome Variations, such as Klinefelter’s Syndrome

RALEIGH, N.C., June 20, 2023 (GLOBE NEWSWIRE) -- Marius Pharmaceuticals, a patient-centric healthcare company specializing in therapies for hypogonadism or…

1 year ago

Statement re: Award of Invention of Innovation FAST Grant

DXS INTERNATIONAL PLC (AQSE: DXSP) Award of Invention of Innovation FAST Grant for Hypertension Management DXS International plc (AQSE: DXSP)…

1 year ago

Avertix’s Guardian™ System, First and Only FDA-Approved Implantable Heart Attack Detection and Warning System, Now Available at AdventHealth Orlando

AdventHealth Orlando performs their first implant of Guardian™ System, revolutionizing cardiac care in Central FloridaEATONTOWN, N.J. and ORLANDO, Fla., June…

1 year ago

Avertix to Participate in the Sidoti Summer Small Cap Conference

EATONTOWN, N.J. and NEW YORK, June 05, 2023 (GLOBE NEWSWIRE) -- Avertix Medical, Inc. (“Avertix” or the “Company”), a company…

1 year ago

HeartSciences Announces Completion of Patient Enrollment for FDA Pivotal Study of MyoVista wavECG

Southlake, Texas, May 09, 2023 (GLOBE NEWSWIRE) -- Heart Test Laboratories, Inc. d/b/a HeartSciences (NASDAQ: HSCS; HSCSW) (“HeartSciences” or the…

2 years ago

Avertix, Maker of First and Only FDA-Approved Implantable Heart Attack Warning System, to Become Publicly Traded via Merger with BIOS Acquisition Corporation

- Transaction values Avertix at an enterprise value of $195 million- Avertix developed the Guardian™ System, the first and only…

2 years ago

Angel Medical Systems, Creator of the Guardian™, First Implantable Cardiac Alert System, Changes Name to Avertix Medical Inc. and Welcomes New CEO and CFO to Drive Continued Growth and Success

New company name chosen to represent focus on ‘averting’ serious cardiac complications with state-of-the-art Guardian™ monitoring and alerting system President…

2 years ago